Quantbot Technologies LP Purchases Shares of 12,363 TG Therapeutics, Inc. $TGTX

Quantbot Technologies LP acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 12,363 shares of the biopharmaceutical company’s stock, valued at approximately $679,000.

Several other large investors have also modified their holdings of the stock. Danske Bank A S purchased a new position in shares of TG Therapeutics in the 3rd quarter valued at $25,000. EverSource Wealth Advisors LLC raised its stake in TG Therapeutics by 51.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 365 shares in the last quarter. Hantz Financial Services Inc. lifted its position in TG Therapeutics by 82.7% in the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 560 shares during the last quarter. Truvestments Capital LLC boosted its stake in TG Therapeutics by 172.4% in the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 1,026 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in TG Therapeutics in the fourth quarter valued at $52,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on TGTX. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research report on Wednesday, July 29th. Bank of America raised their price target on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research note on Tuesday, July 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a $83.00 price target on shares of TG Therapeutics in a research report on Monday, June 22nd. Finally, JPMorgan Chase & Co. boosted their price objective on TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $63.00.

TG Therapeutics Trading Up 1.3%

Shares of TG Therapeutics stock opened at $55.72 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27. The company has a market capitalization of $8.53 billion, a P/E ratio of 20.34, a PEG ratio of 2.36 and a beta of 1.62. TG Therapeutics, Inc. has a 1 year low of $26.76 and a 1 year high of $59.30. The company’s fifty day moving average is $53.36 and its two-hundred day moving average is $41.74.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business had revenue of $240.34 million during the quarter, compared to analysts’ expectations of $229.77 million. During the same period in the previous year, the company posted $0.17 earnings per share. TG Therapeutics’s quarterly revenue was up 70.2% on a year-over-year basis. Analysts forecast that TG Therapeutics, Inc. will post 0.92 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.